Synthetic drug

Last updated

Synthetic drugs refer to substances that are artificially modified from naturally-occurring drugs and are capable of exhibiting both therapeutic and psychoactive effects.

Contents

In the medical setting, synthetic drugs possess psychotropic effects which can cure insomnia. Since there are limited clinical trials and human studies, the pharmacology and drug effects of most of the synthetic drugs are not well-known. Misuse of synthetic drugs can be fatal so take advice from the professionals before use.

Substances that possess the latter effect are known as New Psychoactive Substances (NPS). Their purpose is to mimic the actions of illicit substances by altering the structure of the original drug. By doing so, the “synthesized drug” can appear in the market without being easily detected. However, the uncertainty in the toxic effects of these substances puts the public's health at risk. [1] At present, these drugs are monitored by the Early Warning System (EWS).The major categories of NPS include synthetic stimulants, synthetic cannabinoids and synthetic depressants. Common examples from these categories are phenethylamines, cannabinoids and benzodiazepines. To exert the psychoactive effect, specific receptors such as cannabinoid, dopamine and serotonin receptors are either stimulated or inhibited [2]

Common synthetic drugs

Synthetic cannabinoids

"Spice", the brand name given to synthetic cannabinoids. JBMHH substance abuse coordinator warns of Spice dangers 151022-A-DZ999-972.jpg
"Spice", the brand name given to synthetic cannabinoids.

There are seven major structural groups, which are naphthoylindoles, naphthylmethylindoles, naphthoypyrroles, naphthylmethylindenes, phenylacetylindoles, cyclohexylphenols and classical cannabinoids respectively. [3] Compared with classical cannabinoids, synthetic cannabinoids differ structurally. Some common synthetic cannabinoids are available in the market such as JWH-018, which is the most well-known naphthoylindole and JWH-250, a phenylacetylindole. They are sold under the brand name ”Spice” as a recreational drug over the past decade. [4]

Phenethylamines

Phenethylamines can be classified into ring-substituted and non-ring-substituted form. Ring-substituted Phenethylamines include ‘D-series’ and ‘2C-series’ while common non-ring-substituted Phenethylamines contain Benzodifurans, PMMA, etc. [5]

Novel benzodiazepines(Xanax)

Alprazolam is a generic medication derived from benzodiazepines with the brand name Xanax.

Medical uses

Synthetic cannabinoids can provide psychotropic effects such as relieving nausea and dizziness. Phenethylamine can relieve depressive symptoms while Alprazolam can treat insomnia, panic attack and anxiety. [6] The most common delivery routes of Alprazolam and Phenethylamine are by oral administration. Both of which are available in the dosage forms of pills and tablets. Synthetic cannabinoids are naturally in solid and oil form and are delivered by smoking. [3]

Adverse effects

The adverse effects of synthetic drugs are hard to determine as they usually contain other chemicals with variable concentrations and human studies are limited.

Synthetic cannabinoids can cause cardiovascular problems such as tachyarrhythmia, seizures, psychological disorders and potential carcinogenic effects. Addiction and withdrawal symptoms which are linked to chronic use of synthetic cannabinoid include cognitive disturbances (e.g. difficulties in thinking), ‘profuse sweating’, central nervous system and gastrointestinal disturbances (e.g. nausea and vomiting). [7] [8]

The adverse effect of Phenethylamines depends on the type of the drug. ‘D series’ cause more long-lasting effects than other phenylethylamines such as tachycardia. At high doses, ‘2C series’ produce hallucinogenic and entactogenic effects. [9]

Alprazolam can cause central nervous system disturbances and thoughts of suicide. [6]

Contraindications/Precautions

Synthetic cannabinoids are best avoided in users who suffer from rapid heart rate, vomiting, agitation, confusion and hallucination.

Pregnant women are also not recommended to take phenethylamines as the effects on fetus are not known. In addition, use of phenethylamine might cause people with bipolar disorder to convert from depression to mania and worsened schizophrenia symptoms. As the drug also affects the central nervous system, administration of such drug before surgery is not recommended.

Benzodiazepines can cross the placenta and can be excreted in breast milk therefore Alprazolam is contraindicated in pregnancy and lactation. Alprazolam is a CYP3As substrate so we should avoid CYP3As inhibitors such as cimetidine which is a CYP3A4 inhibitor.

Pharmacology: Pharmacodynamics/Mechanism of Action(MOA)

Synthetic cannabinoids act as Synthetic Cannabinoid Receptor Agonists (SCRA) [10] by binding to cannabinoid receptors CB1 and CB2 . Its binding towards CB1 receptor will lead to receptor phosphorylation that recruits β-arrestin 1 and β-arrestin 2, resulting in a loss of responsiveness and internalization (endocytosis of molecules by the cell). Stimulation of CB1 receptor causes the dissociation of the βγ subunits of pertussis toxin-sensitive G proteins (Gi /Go) from the α subunit (Giα) which then contributes to acute inhibition of synaptic neurotransmitter release. β-arrestin can also stimulate the mitogen-activated protein kinase, thus inducing additional cellular effects. Synthetic cannabinoids can also bind to receptors other than CB1 and CB2 to activate inotropic transient receptor potential channels for cell membrane depolarization and Ca2+ influx. [11]

This diagram shows the interaction between the cannabinoid agonists and CB1 & CB2 receptors. Cannabinoid Receptors With THC-2.svg
This diagram shows the interaction between the cannabinoid agonists and CB1 & CB2 receptors.

Phenethylamines, which can act as either stimulants or hallucinogens, are indirectly acting sympathomimetic amines. Stimulants can modulate the levels and action of monoamine neurotransmitters such as dopamine, serotonin and noradrenaline for vasoconstriction and elevation in blood pressure. For example, 10-100 μM amphetamine can reach the vasoconstriction effect. Hallucinogen (psychedelics) can mediate specific serotonin-receptor activities and produce hallucinations. They may have residue stimulant activity as well. In some animal studies, Phenethylamines have negative inotropism in isolated cardiac tissues of rats due to stimulation of TAAR1, which is in contrast with human pharmacology. [12]

Alprazolam binds to GABA type-A benzodiazepine receptor sites which are the members of the pentameric ligand-gated ion channel (PLGIC) superfamily. It mediates phasic inhibition and extrasynaptically to mediate tonic inhibition. Once attached, conformational changes occur which stabilize the receptors and inhibitory signals are produced [13]

Pharmacokinetics

Synthetic cannabinoids are delivered by smoking. In a human study, after 50 μg/kg smoked JWH-018 are delivered, one male and a female have their serum concentration of 8.1 and 10.2 μg/L respectively after 5 minutes, down to 4.6 and 6.1 μg/L after 15 minutes, suggesting the biological half-life of JWH-018 is short. 13 phase 1 metabolites are identified. Monohydroxylated and dihydrodiol metabolites are most prevalent metabolites of synthetic cannabinoids. UGT1A1, UGT1A3, UGT1A9, UGT1A10 and UGT2B7 isoenzymes were primarily responsible for JWH-018 and JWH-073 metabolites’ conjugation and had high affinity for hydroxylated metabolites (Km=12–18 mmol/L). Generation of JWH-018-N-4- and 5-hydroxypentyl (JWH-018 metabolites) was primarily mediated by CYP2C9 followed by CYP1A2 and CYP2C19. CYP3A4 catalyzed JWH-018-N-4-hydroxypentyl production but with lower activity than CYP1A2 and CP2C19. The drugs are mainly excreted as urine. [11]

Phenethylamines are first-order kinetics with half life of 5 to 10 minutes which are absorbed by ingestion. The drugs have low concentration in the brain due to low biological half-life. It is difficult to measure the plasma concentration due to low stability of Phenethylamine. There are two possible metabolism pathways. The first possible pathway is metabolism by MAO-B (an intracellular enzyme mainly in the brain and tightly bound to the outer membrane of mitochondria which deaminates free primary and secondary amines) to form phenylacetic acid due to MAO-B selectivity on non-polar aromatic amines. Then, the metabolites undergo N-methylation by non-specific N-methyltransferase(NMT) or by phenylethanolamine-N-methyltransferase (PNMT) (found in the adrenal medulla) to form secondary amines and sympathetic neurotransmitter noradrenaline. The second possible pathway is deamination of the drug by the semi-carbazide-sensitive amine oxidases (SSAO) (found in the vascular tissue and have similar metabolism to MAO). An alpha-methyl side chain renders the drug immune to deamination in the gut. The drugs are mainly excreted in feces and urine. [14]

Alprazolam has high oral bioavailability (84-91%) in which its maximum plasma concentration (Cmax) is reached after 1 to 2 hours. When taken with food, Cmax is increased by 25%. The half-life profile of this drug for different populations is illustrated in the following table:

Half-life profile
PopulationHalf-life (hrs)
Healthy individuals11.2
Obese10.7-15.8
Alcoholic liver disease19.7

In terms of race, the half-life is 25% higher in Asian patients compared to Caucasians. For the extended-release formulation, it has a half-life of 10.7-15.8 hours in healthy adult patients. Alprazolam has a volume of distribution following oral administration of 0.8-1.3L/kg. Its protein binding in plasma is 80% (mainly albumin bound) and capable of crossing the blood-brain barrier. It is metabolized to less effective metabolites by various CYP450 enzymes including CYP3A4, CYP3A5, CYP3A7, and CYP2C9. The majority of alprazolam metabolism is mediated by hydroxylation via CYP3As. 4-hydroxyalprazolam has 20% the binding affinity of the parent drug, alpha-hydroxyalprazolam has 66% the affinity, and the benzophenone metabolite has <1% the affinity. The drugs are mainly excreted in urine as unchanged Alprazolam. <10% of the dose is eliminated as alpha-hydroxy-alprazolam and 4-hydroxy-alprazolam. [13]

Chemistry

Detection in body fluids

Drug detection in body fluids requires specific reference data from the target drug. A common pitfall in the detection of New Psychoactive Substances (NPS) is the lack of reference data available for spectrometers to identify the presence of structurally modified illicit substances. Another drug detection technique, immunoassay, relies on active antibodies to detect the target drug by selectivity. If the drug is structurally modified, the original antibodies will respond in a different fashion which will give false positive or negative results. [15]

A diagram illustrating the basic logistics of immunoassay. Mass Spectrometric Immunoassay.png
A diagram illustrating the basic logistics of immunoassay.

Structure-activity relationship

Synthetic cannabinoids

Synthetic cannabinoids, members of the aminoalkylindole class, made its first appearance in 2008. It was given the name 'JWH’ because a chemist called John W. Huffman synthesized them in the 1960s. Most synthetic analogs of cannabinoids mimic the structure of 9-tetrahydrocannabinol (THC), which makes them an agonist to the CB1(Type I) and CB2 (Type II) cannabinoid receptors. CB1 in particular, is expressed in the central nervous system and largely responsible for the psychoactive effect.. [16]

A typical agonist consists of the following components: head, linker core and tail. Altering the structure from each component will affect the drug's affinity to the cannabinoid receptors. For instance, when a fluoride or nitrile group is attached to the carbon chains, the affinity for CB1 will increase. The aromatic rings from the aminoalkylindole class also play the role of enhancing the affinity by forming a hydrophobic cavity to stabilize the CB1 receptors. [17] As legislation becomes tightened under the monitoring of Early Warning System (EWS), attempts are made to alter the structure which produce new analogues such as the Cyclopropylindoles (UR-144) and adamantylindoles (APINACA). [18]

"JWH" is the notation given to the family of aminoalkylindoles. Shown above is the member of the JWH series, known as JWH-018 JWH018.svg
"JWH" is the notation given to the family of aminoalkylindoles. Shown above is the member of the JWH series, known as JWH-018

Novel benzodiazepines

Analogues of novel benzodiazepines are able to possess antibacterial activities. When they are tested against various bacterial strains, the isoxazolyl analogues with the p-chlorophenyl group (p-CIC6H4) attached have shown to be the most effective agent against the majority of the strains. Furthermore, attachment of an electron withdrawing groups and heterocyclic rings such as thiophene and furan will increase the inhibitory effect against bacteria. Novel benzodiazepines can also modulate the Central Nervous System by docking to the human dopamine transporter D3. Enantiomers of imidazole [1,4] diazepines with either a methyl group (CH3) or a propyl group attached enhance the binding affinity towards human dopamine D3 receptors. [19]

A Furan ring. This component increases the antibacterial effects of novel benzodiazepine analogue Furan structure.svg
A Furan ring. This component increases the antibacterial effects of novel benzodiazepine analogue
The alpha and beta carbon positions of Phenylethylamine are shown in this structure Phenylethylamine numbered.svg
The alpha and beta carbon positions of Phenylethylamine are shown in this structure

Phenylethylamine

In general, phenylethylamine consists of an aromatic ring connected to an amine group which is 2 carbons away. [20] Each type of phenylethylamine differs by the substitutions at the alpha and beta carbon position. When a methyl group is attached at the alpha position, the compound becomes amphetamines which has the ability to modulate the 5HT-2A serotonin receptors. Eventually, the activated receptors cause hallucinations. [21] To ensure sufficient binding, the agonists must contain a primary amine, methoxy group and hydrophobic functional groups. [22]

Legality and Regulation

The Early Warning System (EWS), operated by the European Monitoring Centre for Drugs and Drug addiction (EMCDDA), overseas illicit substances that appear in the market. Established in 1997, It formed part of the framework that allows the European Union to rapidly detect NPS that pose a risk to the public's health. Due to the tightening of legislation, most NPS are now illegal in the UK and Germany. Upon the emergence of NPS, this agency responds in the following manner:

StepsProcedure
1Formal notification
2Monitoring and response
3Initial report writing

[23]

When the EWS detects a new drug, the substance will be reported to EMCDDA along with any analytical data such as structures, analysts or components found pertaining to that particular drug. Then, an interconnected system is established to closely monitor the development of the substance. If harm is induced, an initial report is drafted to document the adverse effects of the drug.

In recent years, a new type of benzodiazepine known as ‘Designer benzodiazepines’ are becoming available in Europe. It is based on the premise of modifying the structure of illicit drugs to evade international control measures. By early 2021, EMCDDA has monitored 30 designer benzodiazepines through the EWS. However, not much information is available regarding the market size of new benzodiazepines. Seizures reports from police and customs authorities have shown that new benzodiazepine is not of great interest compared to other NPS groups. In 2019, 4% of police seizures is attributed to benzodiazepines. [24]

Related Research Articles

<span class="mw-page-title-main">Cannabinoid</span> Compounds found in cannabis

Cannabinoids are several structural classes of compounds found in the cannabis plant primarily and most animal organisms or as synthetic compounds. The most notable cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC) (delta-9-THC), the primary psychoactive compound in cannabis. Cannabidiol (CBD) is also a major constituent of temperate cannabis plants and a minor constituent in tropical varieties. At least 113 distinct phytocannabinoids have been isolated from cannabis, although only four have been demonstrated to have a biogenetic origin. It was reported in 2020 that phytocannabinoids can be found in other plants such as rhododendron, licorice and liverwort, and earlier in Echinacea.

<span class="mw-page-title-main">JWH-018</span> Chemical compound

JWH-018 (1-pentyl-3-(1-naphthoyl)indole, NA-PIMO or AM-678) is an analgesic chemical from the naphthoylindole family that acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with some selectivity for CB2. It produces effects in animals similar to those of tetrahydrocannabinol (THC), a cannabinoid naturally present in cannabis, leading to its use in synthetic cannabis products that in some countries are sold legally as "incense blends".

<span class="mw-page-title-main">JWH-073</span> Chemical compound

JWH-073, a synthetic cannabinoid, is an analgesic chemical from the naphthoylindole family that acts as a full agonist at both the CB1 and CB2 cannabinoid receptors. It is somewhat selective for the CB1 subtype, with affinity at this subtype approximately 5× the affinity at CB2. The abbreviation JWH stands for John W. Huffman, one of the inventors of the compound.

<span class="mw-page-title-main">JWH-015</span> Chemical compound

JWH-015 is a chemical from the naphthoylindole family that acts as a subtype-selective cannabinoid agonist. Its affinity for CB2 receptors is 13.8 nM, while its affinity for CB1 is 383 nM, meaning that it binds almost 28 times more strongly to CB2 than to CB1. However, it still displays some CB1 activity, and in some model systems can be very potent and efficacious at activating CB1 receptors, and therefore it is not as selective as newer drugs such as JWH-133. It has been shown to possess immunomodulatory effects, and CB2 agonists may be useful in the treatment of pain and inflammation. It was discovered and named after John W. Huffman.

<span class="mw-page-title-main">JWH-307</span> Chemical compound

JWH-307 is an analgesic drug used in scientific research, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors. It is somewhat selective for the CB2 subtype, with a Ki of 7.7 nM at CB1 vs 3.3 nM at CB2. It was discovered by, and named after, John W. Huffman. JWH-307 was detected as an ingredient in synthetic cannabis smoking blends in 2012, initially in Germany.

<span class="mw-page-title-main">Synthetic cannabinoids</span> Designer drugs

Synthetic cannabinoids are a class of designer drug molecules that bind to the same receptors to which cannabinoids in cannabis plants attach. These novel psychoactive substances should not be confused with synthetic phytocannabinoids or synthetic endocannabinoids from which they are in many aspects distinct.

<span class="mw-page-title-main">AM-694</span> Chemical compound

AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole) is a designer drug that acts as a potent and selective agonist for the cannabinoid receptor CB1. It is used in scientific research for mapping the distribution of CB1 receptors.

<span class="mw-page-title-main">JWH-007</span> Chemical compound

JWH-007 is an analgesic chemical from the naphthoylindole family, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors. It was first reported in 1994 by a group including the noted cannabinoid chemist John W. Huffman. It was the most active of the first group of N-alkyl naphoylindoles discovered by the team led by John W Huffman, several years after the family was initially described with the discovery of the N-morpholinylethyl compounds pravadoline (WIN 48,098), JWH-200 (WIN 55,225) and WIN 55,212-2 by the Sterling Winthrop group. Several other N-alkyl substituents were found to be active by Huffman's team including the n-butyl, n-hexyl, 2-heptyl, and cyclohexylethyl groups, but it was subsequently determined that the 2-methyl group on the indole ring is not required for CB1 binding, and tends to increase affinity for CB2 instead. Consequently, the 2-desmethyl derivative of JWH-007, JWH-018, has slightly higher binding affinity for CB1, with an optimum binding of 9.00 nM at CB1 and 2.94 nM at CB2, and JWH-007 displayed optimum binding of 9.50 nM at CB1 and 2.94 nM at CB2.

<span class="mw-page-title-main">JWH-164</span> Chemical compound

JWH-164 is a synthetic cannabinoid receptor agonist from the naphthoylindole family. It has approximately equal affinity for the CB1 and CB2 receptors, with a Ki of 6.6 nM at CB1 and 6.9 nM at CB2. JWH-164 is a positional isomer of the related compound JWH-081, but with a methoxy group at the 7-position of the naphthyl ring, rather than the 4-position as in JWH-081. Its potency is intermediate between that of JWH-081 and its ring unsubstituted derivative JWH-018, demonstrating that substitution of the naphthyl 7-position can also result in increased cannabinoid receptor binding affinity.

<span class="mw-page-title-main">AM-2201</span> Chemical compound

AM-2201 is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor. It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University.

<span class="mw-page-title-main">JWH-175</span> Chemical compound

JWH-175 is a drug from the naphthylmethylindole family which acts as a cannabinoid receptor agonist. It was invented by the scientist John W. Huffman and colleagues at Clemson University. JWH-175 is closely related to the widely used cannabinoid designer drug JWH-018, but with the ketone bridge replaced by a simpler methylene bridge. It is several times weaker than JWH-018, having a binding affinity at the CB1 receptor of 22 nM, though some derivatives substituted at the 4-position of the naphthyl ring have potency more closely approaching that of the equivalent naphthoylindoles. This makes JWH-175 considerably less potent than most synthetic cannabinoid drugs used in synthetic cannabis blends, and it is unclear if JWH-175 has ever been used for this purpose. However it has still been explicitly banned in several jurisdictions including Russia and some Australian states, in order to stop its potential use as an ingredient in such products. In the United States, all CB1 receptor agonists of the 3-(1-naphthylmethane)indole class such as JWH-175 are Schedule I Controlled Substances.

<span class="mw-page-title-main">MDA-19</span> Chemical compound

MDA-19 (also known as BZO-HEXOXIZID) is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor, though with some variation between species. In animal studies it was effective for the treatment of neuropathic pain, but did not effect rat locomotor activity in that specific study. The pharmacology of MDA-19 in rat cannabinoid receptors have been demonstrated to function differently than human cannabinoid receptors with MDA-19 binding to human CB1 receptors 6.9× higher than rat CB1 receptors.

<span class="mw-page-title-main">UR-144</span> Chemical compound

UR-144 (TMCP-018, KM-X1, MN-001, YX-17) is a drug invented by Abbott Laboratories, that acts as a selective full agonist of the peripheral cannabinoid receptor CB2, but with much lower affinity for the psychoactive CB1 receptor.

<span class="mw-page-title-main">MAM-2201</span> Chemical compound

MAM-2201 is a drug that presumably acts as a potent agonist for the cannabinoid receptors. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in the Netherlands and Germany in June 2011 as an ingredient in synthetic cannabis smoking blends. Like RCS-4 and AB-001, MAM-2201 thus appears to be a novel compound invented by "research chemical" suppliers specifically for grey-market recreational use. Structurally, MAM-2201 is a hybrid of two known cannabinoid compounds JWH-122 and AM-2201, both of which had previously been used as active ingredients in synthetic cannabis blends before being banned in many countries.

<span class="mw-page-title-main">AB-005</span> Group of stereoisomers

AB-005 or [1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone is a designer drug offered by online vendors as a cannabimimetic agent. The structure and pharmacological activity of AB-005 was published in 2010, prior to its commercial availability in 2012, where it was reported to have high affinity for both CB1 (Ki = 5.5 nM) and CB2 receptors (Ki = 0.48 nM). AB-005 features groups found in other previously reported synthetic cannabinoids: the tetramethylcyclopropane group of UR-144 and XLR-11 as well as the (1-methyl-2-piperidinyl)methyl substituent of AM-1248 and AM-1220. No information regarding the in vivo activity of AB-005 has been published, and only anecdotal reports are known of its psychoactivity in humans.

<span class="mw-page-title-main">SDB-005</span> Chemical compound

SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.

<span class="mw-page-title-main">MDMB-CHMICA</span> Chemical compound

MDMB-CHMICA is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. While MDMB-CHMICA was initially sold under the name "MMB-CHMINACA", the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analogue of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA.

<span class="mw-page-title-main">Bromazolam</span> Triazolobenzodiazepine

Bromazolam (XLI-268) is a triazolobenzodiazepine (TBZD) which was first synthesised in 1976, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified by the EMCDDA in Sweden in 2016. It is the bromo instead of chloro analogue of alprazolam and has similar sedative and anxiolytic effects to it and other benzodiazepines. Bromazolam is a non subtype selective agonist at the benzodiazepine site of GABAA receptors, with a binding affinity of 2.81nM at the α1 subtype, 0.69nM at α2 and 0.62nM at α5.

<span class="mw-page-title-main">EG-018</span> Chemical compound

EG-018 is a carbazole-based synthetic cannabinoid that has been sold online as a designer drug. It acts as a partial agonist of the CB1 and CB2 receptor, with reasonably high binding affinity, but low efficacy in terms of inducing a signaling response.

References

  1. ↑ Rinaldi, Raffaella; Bersani, Giuseppe; Marinelli, Enrico; Zaami, Simona (2020-03-07). "The rise of new psychoactive substances and psychiatric implications: A wide‐ranging, multifaceted challenge that needs far‐reaching common legislative strategies". Human Psychopharmacology: Clinical and Experimental. 35 (3): e2727. doi:10.1002/hup.2727. ISSN   0885-6222. PMID   32144953. S2CID   212621941.
  2. ↑ Shafi, Abu; Berry, Alex J.; Sumnall, Harry; Wood, David M.; Tracy, Derek K. (2020-09-26). "New psychoactive substances: a review and updates". Therapeutic Advances in Psychopharmacology. 10: 204512532096719. doi:10.1177/2045125320967197. ISSN   2045-1253. PMC   7750892 . PMID   33414905.
  3. 1 2 "Synthetic cannabinoids and 'Spice' drug profile | www.emcdda.europa.eu". www.emcdda.europa.eu. Retrieved 2022-03-16.
  4. ↑ Banister, Samuel D.; Stuart, Jordyn; Kevin, Richard C.; Edington, Amelia; Longworth, Mitchell; Wilkinson, Shane M.; Beinat, Corinne; Buchanan, Alexandra S.; Hibbs, David E.; Glass, Michelle; Connor, Mark (2015-05-08). "Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135". ACS Chemical Neuroscience. 6 (8): 1445–1458. doi:10.1021/acschemneuro.5b00107. ISSN   1948-7193. PMID   25921407.
  5. ↑ "Details for Phenethylamines". www.unodc.org. Retrieved 2022-03-16.
  6. 1 2 "Alprazolam: MedlinePlus Drug Information". medlineplus.gov. Retrieved 2022-04-20.
  7. ↑ "Synthetic cannabinoids: What are they? What are their effects? | HSB | NCEH". www.cdc.gov. 2022-04-11. Retrieved 2022-04-20.
  8. ↑ Cooper, Ziva D. (2016-06-28). "Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal". Current Psychiatry Reports. 18 (5): 52. doi:10.1007/s11920-016-0694-1. ISSN   1523-3812. PMC   4923337 . PMID   27074934.
  9. ↑ "Details for Phenethylamines". www.unodc.org. Retrieved 2022-04-20.
  10. ↑ "Details for Synthetic cannabinoids". www.unodc.org. Retrieved 2022-04-20.
  11. 1 2 Walsh, Kenneth B.; Andersen, Haley K. (2020-08-25). "Molecular Pharmacology of Synthetic Cannabinoids: Delineating CB1 Receptor-Mediated Cell Signaling". International Journal of Molecular Sciences. 21 (17): 6115. doi: 10.3390/ijms21176115 . ISSN   1422-0067. PMC   7503917 . PMID   32854313.
  12. ↑ Broadley, Kenneth J. (2009-12-04). "The vascular effects of trace amines and amphetamines". Pharmacology & Therapeutics. 125 (3): 363–375. doi:10.1016/j.pharmthera.2009.11.005. ISSN   1879-016X. PMID   19948186.
  13. 1 2 "Xanax: Uses, Dosage, Side Effects & Warnings". Drugs.com. Retrieved 2022-04-20.
  14. ↑ Janssen, Paul A. J.; Leysen, Josée E.; Megens, Anton A. H. P.; Awouters, Frans H. L. (1999-09-01). "Does phenylethylamine act as an endogenous amphetamine in some patients?". The International Journal of Neuropsychopharmacology. 2 (3): 229–240. doi: 10.1017/s1461145799001522 . ISSN   1461-1457. PMID   11281991.
  15. ↑ Favretto, Donata; Pascali, Jennifer P.; Tagliaro, Franco (2013-04-23). "New challenges and innovation in forensic toxicology: Focus on the "New Psychoactive Substances"". Journal of Chromatography A. 1287: 84–95. doi:10.1016/j.chroma.2012.12.049. ISSN   0021-9673. PMID   23332303.
  16. ↑ Pintori, Nicholas; Loi, Barbara; Mereu, Maddalena (2017-05-14). "Synthetic cannabinoids: the hidden side of Spice drugs". Behavioural Pharmacology. 28 (6): 409–419. doi:10.1097/fbp.0000000000000323. ISSN   0955-8810. PMID   28692429. S2CID   4913772.
  17. ↑ Patel, Monica; Finlay, David B.; Glass, Michelle (2021-11-26). "Biased agonism at the cannabinoid receptors – Evidence from synthetic cannabinoid receptor agonists". Cellular Signalling. 78: 109865. doi:10.1016/j.cellsig.2020.109865. ISSN   0898-6568. PMID   33259937. S2CID   227254963.
  18. ↑ CE, Smith, JP Sutcliffe, OB Banks (2015-06-02). An overview of recent developments in the analytical detection of new psychoactive substances (NPSs). Royal Society of ChemistryLondon. OCLC   1269494147.{{cite book}}: CS1 maint: multiple names: authors list (link)
  19. ↑ Arora, Nidhi; Dhiman, Prashant; Kumar, Shubham; Singh, Gurpreet; Monga, Vikramdeep (2020-02-17). "Recent advances in synthesis and medicinal chemistry of benzodiazepines". Bioorganic Chemistry. 97: 103668. doi:10.1016/j.bioorg.2020.103668. ISSN   0045-2068. PMID   32106040. S2CID   211556193.
  20. ↑ Khan, JaVed I.; Kennedy, Thomas J.; Christian, Donnell R. (2012), "Phenethylamines", Basic Principles of Forensic Chemistry, Totowa, NJ: Humana Press, pp. 157–176, doi:10.1007/978-1-59745-437-7_13, ISBN   978-1-934115-06-0 , retrieved 2022-03-16
  21. ↑ Valento, Matthew; Lebin, Jacob (2017-07-06). "Emerging Drugs of Abuse: Synthetic Cannabinoids, Phenylethylamines (2C Drugs), and Synthetic Cathinones". Clinical Pediatric Emergency Medicine. 18 (3): 203–211. doi:10.1016/j.cpem.2017.07.009. ISSN   1522-8401.
  22. ↑ E, Isberg, Vignir Paine, James Leth-Petersen, Sebastian Kristensen, Jesper Langgaard Gloriam, David (2013). Structure-activity relationships of constrained phenylethylamine ligands for the serotonin 5-ht2 receptors. OCLC   1035205954.{{cite book}}: CS1 maint: multiple names: authors list (link)
  23. ↑ Evans-Brown, Michael; Sedefov, Roumen (2018), "Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control Measures", New Psychoactive Substances, Cham: Springer International Publishing, vol. 252, pp. 3–49, doi:10.1007/164_2018_160, ISBN   978-3-030-10560-0, PMID   30194542 , retrieved 2022-03-16
  24. ↑ European Monitoring Centre for Drugs and Drug Addiction. (2021). New benzodiazepines in Europe: a review. LU: Publications Office. doi:10.2810/725973. ISBN   9789294976413.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.